StreetInsider.com News Articles

Form D Polyrizon Ltd.

Thu, 10 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260910/27048615.html

Polyrizon launches $4M registered direct offering and private placement

Thu, 03 Sep 2026 08:50:37 -0400

Polyrizon Ltd. (NASDAQ: PLRZ), a development-stage biotech company based in Raanana, Israel, announced it has entered into definitive agreements with a single institutional investor for a registered direct offering and concurrent private placement, with aggregate gross proceeds expected to reach approximately $4.0 million.

The transactions involve the sale of 333,333 units, each consisting of one ordinary share, or one pre-funded warrant to purchase one ordinary share, and one common warrant to purchase one ordinary share. The combined offering price is $12.00 per unit, or $11.99999 per pre-funded unit. In the registered direct offering, the company agreed to sell 232,500 ordinary shares

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Thu, 03 Sep 2026 08:50:00 -0400

RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $4.0 million.

The transactions

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Thu, 03 Sep 2026 08:50:00 -0400

The transactions

Polyrizon signs all five U.S. sites for NASARIX allergy trial

Wed, 02 Sep 2026 07:32:54 -0400

Polyrizon Ltd. (Nasdaq: PLRZ) has completed contracts with all five U.S. clinical sites selected for its first-in-human study of NASARIX™ Allergy Blocker (PL-14), according to a company statement.

The planned study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis. The trial aims to enroll up to 120 randomized patients, assigned in a 1:1 ratio to receive either NASARIX™ or an isotonic saline nasal spray control.

The primary efficacy endpoint will measure the difference between treatment groups in mean daily reflective Total Nasal Symptom Score over

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Wed, 02 Sep 2026 07:32:00 -0400

Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).

With the execution of these final agreements, Polyrizon has completed the contracting with all five U.S. clinical sites selected for the study, marking an important operational milestone and moves the NASARIX™ program into study execution. The planned first-in-human study is a prospective, multicenter, randomized, single-blind,

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Wed, 02 Sep 2026 07:32:00 -0400

Form 6-K Polyrizon Ltd. For: Aug 20

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956044.html

Form 6-K Polyrizon Ltd. For: Aug 20

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956044.html

Polyrizon completes site contracts for Nasarix allergy trial

Thu, 20 Aug 2026 09:30:29 -0400

Polyrizon Ltd. (Nasdaq: PLRZ) has completed contracting with all five U.S. clinical sites selected to participate in its planned study of NASARIX™ Allergy Blocker (PL-14), according to a press release from the Israel-based development-stage biotech company.

The planned first-in-human study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis. The study aims to enroll up to 120 randomized patients, assigned in a 1:1 ratio to receive either NASARIX™ or an isotonic saline nasal spray as a control.

The study's primary efficacy endpoint will measure the difference

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Thu, 20 Aug 2026 09:30:00 -0400

Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients

Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).

With the execution of these final agreements, Polyrizon has now completed the contracting process with all five clinical sites selected to participate in the

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Thu, 20 Aug 2026 09:30:00 -0400

Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients

With the execution of these final agreements, Polyrizon has now completed the contracting process with all five clinical sites selected to participate in the

Form SCHEDULE 13G/A Polyrizon Ltd. Filed by: MMCAP International Inc. SPC

Fri, 14 Aug 2026 15:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26929425.html

Form SCHEDULE 13G/A Polyrizon Ltd. Filed by: MMCAP International Inc. SPC

Fri, 14 Aug 2026 15:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26929425.html

Form 6-K Polyrizon Ltd. For: Jul 13

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762392.html

Form 6-K Polyrizon Ltd. For: Jul 13

Mon, 13 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260713/26762392.html

Core AI Holdings names Arie Goor as CFO, effective July 1

Tue, 07 Jul 2026 08:20:14 -0400

Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.

Goor, 43, brings more than 15 years of executive financial leadership experience in corporate finance, capital markets, and strategic transactions across the biotechnology, medical device, and technology sectors.

Before joining Core AI Holdings, Goor served as CFO of NYSE-listed Regentis Biomaterials (RGNT) from October 2022 to January 2026, and as CFO of Revium Rx from June 2023 to May 2026. He has led initial public offerings and capital markets transactions on exchanges including Nasdaq, the Australian Securities Exchange, the TSX Venture Exchange,

Core AI Holdings names Arie Goor as CFO, effective July 1

Tue, 07 Jul 2026 08:20:14 -0400

Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.

Core AI Holdings names Arie Goor as CFO, effective July 1

Tue, 07 Jul 2026 08:20:14 -0400

Core AI Holdings, Inc. (NASDAQ: CHAI) announced the appointment of Arie Goor as Chief Financial Officer, effective July 1, 2026.

Form 6-K Polyrizon Ltd. For: Jul 02

Thu, 02 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26727396.html

Form 6-K Polyrizon Ltd. For: Jul 02

Thu, 02 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26727396.html

Polyrizon completes biocompatibility tests for NASARIX nasal spray

Thu, 02 Jul 2026 07:34:18 -0400

Polyrizon Ltd. (Nasdaq: PLRZ), an Israel-based development-stage biotech company, announced that its NASARIX™ Allergy Blocker nasal spray has completed a biocompatibility evaluation program, with all required biological safety tests meeting predetermined acceptance criteria.

The evaluation program was designed in accordance with ISO 10993 standards, FDA guidance, and European regulatory requirements. Testing covered cytotoxicity, sensitization, irritation and intracutaneous reactivity, material-mediated pyrogenicity, and acute systemic toxicity. Long-term systemic toxicity was assessed through a toxicological risk assessment conducted under ISO 10993-17.

The evaluation was based on the final NASARIX™ product configuration and incorporated assessments of formulation components, manufacturing processes, packaging materials, and intended patient exposure.

NASARIX™

Polyrizon completes biocompatibility tests for NASARIX nasal spray

Thu, 02 Jul 2026 07:34:18 -0400

NASARIX™

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Thu, 02 Jul 2026 07:32:00 -0400

Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocompatibility evaluation program for its proprietary NASARIX^TM Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.

The comprehensive evaluation program was designed in accordance with internationally recognized standards for biological safety assessment of medical devices, including the ISO 10993 series, FDA guidance, and applicable European regulatory requirements. The program was developed to assess the safety and biocompatibility

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Thu, 02 Jul 2026 07:32:00 -0400